Current State of Antibiotic Resistance of Pathogens Causing Community-Acquired Urinary Tract Infections in Russia: «DARMIS» Study (2010–2011)

Clinical Microbiology and Antimicrobial Chemotherapy. 2012; 14(4):280-302

​ Palagin I.S., Sukhorukova M.V., Dekhnich A.V., Edelstein M.V., Shevelev A.N., Grinev A.V., Perepanova T.S., Kozlov R.S., «DARMIS» Study Group
urinary tract infections uropathogens antibiotic resistance empiric therapy
Section
Antimicrobial Resistance
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2012; 14(4):280-302

Objective.

Objectives. To investigate etiology and susceptibility of pathogens causing community-acquired urinary tract infections (UTIs) in different regions of Russia in various patients’ subsets to the most clinically used antimicrobials.

Materials and Methods.

A total of 903 uropathogens isolated from urine samples of children and adults of all age groups with acute (and recurrence of chronic) community-acquired UTIs, including pregnant women with asymptomatic bacteriuria were collected in 26 centers of 18 cities in Russia during 2010–2011 and included in the «DARMIS» study.

Results.

Among the identified microorganisms the most prevalent uropathogens were Enterobacteriaceae spp. (85.4%) and E. coli (65.1%). The most active oral drugs against E. coli were fosfomycin (98.3%), nitrofurantoin (97.8%) and ceftibuten (93.4%). Furazidin also demonstrated a high rate of activity against E. coli strains. Out of oral antibiotics only fosfomycin was active against more than 90% of all Enterobacteriaceae spp. strains (91.8%), whereas nitrofurantoin and ceftibuten demonstrated activity against 85.6% and 89.5% of strains respectively. Out of parenteral drugs the most active against E. coli were meropenem and imipenem with totally no resistant strains observed. Also high in vitro activity demonstrated ertapenem (99.8%), amikacin (97.9%), piperacillin/tazobactam (93.0%), gentamicin (90.1%) and III–IV generation cephalosporins. Carbapenems were the most active parenteral antimicrobials against all Enterobacteriaceae spp. strains as well.

Conclusions.

Susceptibility results shown in «DARMIS» study enable the evaluation of appropriate antimicrobial choice for empirical treatment of community-acquired UTI in Russia.

  • 1. Hooton T.M. Uncomplicated urinary tract infection. New Engl J Med 2012; 366:1028-37.
  • 2. Kahlmeter G., ECO.SENS. An international survey on the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project. J Antimicrob Chemother 2003; 51:69-76.
  • 3. Nicole L. Epidemiology of urinary tract infections. Infect Med 2001; 18:153-62.
  • 4. Foxman B. Recurring urinary tract infection: incidence and risk factors. Am J Public Health 1990; 80:331-3.
  • 5. Shapiro E.D. Infections of the urinary tract. Pediatr Infect Dis J 1992; 11:165-8.
  • 6. MacLean A.B. Urinary tract infection in pregnancy. Int J Antimicrob Agents 2001; 17:273-277.
  • 7. Warren J.W., Abrutyn E., Hebel J.R., Johnson J.R., Schaeffer A.J., Stamm W.E. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis 1999; 29(4):745-58.
  • 8. Рафальский В.В., Страчунский Л.С., Кречикова О.И., Эйдельштейн И.А. и др. Резистентность возбудителей амбулаторных инфекций мочевыводящих путей по данным многоцентровых микробиологических исследований UTIAP-I и UTIAP-II. Урология 2004; 2:13-17.
  • 9. Многоцентровое исследование резистентности возбудителей амбулаторных инфекций мочевыводящих путей (UTIAP-3). Научный отчет НИИ антимикробной химиотерапии ГОУ ВПО «Смоленская государственная медицинская академия» Федерального агентства по здравоохранению и социальному развитию, 2006.
  • 10. Рафальский В.В., Страчунский Л.С. и др. Резистентность возбудителей неосложненных инфекций мочевых путей в России. Урология 2006; 5:34-37.
  • 11. Коровина Н.A., Захарова И.Н., Страчунский Л.С. и др. Практические рекомендации по антибактериальной терапии инфекций мочевой системы внебольничного происхождения у детей. Клин микробиол антимикроб химиотер 2002; 4: 337-46.
  • 12. Рафальский В.В., Кулаков В.И., Анкирская А.С., Страчунский Л.С., Шевелев А.Н. и др. Антибактериальная терапия инфекций мочевыводящих путей у беременных. Клин микробиол антимикроб химиотер 2004; 3:218-24.
  • 13. Schito G.C., Naber K.G., Botto H., Palou J., Mazzei T., Marchese A. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents 2009; 34:407-13.
  • 14. Grabe M., Bjerklund-Johansen T.E., Botto H., et al. Guidelines on urological infections. Uroweb 2012. (http://www.uroweb.org/fileadmin/guidelines/2012_Guidelines_large_text_print_total_file.pdf).
  • 15. European Committee on Antimicrobial Susceptibility Testing. Breakpoint Tables for interpretation of MICs and zone diameters. Version 2.0 (from 2012-01-01).
  • 16. CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-second information supplement. CLSI document M100-S22. Wayne, PA: Clinical and Laboratory Standards Institute; 2012.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared